Trial Profile
Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2016
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Feb 2012 Actual patient number 92 added as reported by ClinicalTrials.gov.
- 08 Feb 2012 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.